Bristol-Myers Squibb’s $2.4 Billion Acquisition of Medarex

On July 22, 2009, Bristol-Myers Squibb Company announced entry into a definitive merger agreement whereby it will acquire Medarex, Inc., a biopharmaceutical company with a specific focus on the discovery, development and potential commercialization of fully human antibody-based therapeutics, for approximately $2.4 billion. Under the terms of the agreement, Bristol-Myers will commence a cash tender offer to purchase all the outstanding shares of Medarex for $16.00 per share.

The lawyers involved in this transaction include partners Susan Webster and Thomas E. Dunn and associates Sarah S. Jones, Leigh M. Harlan and Jean-Paul Sevilla on corporate matters; partner Eric W. Hilfers and associates Jarrett R. Hoffman, Jennifer R. Graff and Jared R. Whalen on executive compensation and benefits matters; partners Stephen L. Gordon and Lauren Angelilli and associates Audry X. Casusol and Christopher K. Fargo on tax matters; partner Elizabeth L. Grayer and associate Robin C. Landis on antitrust matters; and partner Jeffrey A. Smith and associate Annmarie M. Terraciano on environmental matters. Summer associates Kristin N. Fasullo, Ankur N. Patel, Allison M. Pecher, Sohail S. Ramirez and Michelle M. Shenker also worked on corporate matters.